SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-23-006178
Filing Date
2023-02-13
Accepted
2023-02-13 07:18:12
Documents
14
Period of Report
2023-02-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10048029_8k.htm   iXBRL 8-K 33712
2 EXHIBIT 99.1 brhc10048029_ex99-1.htm EX-99.1 292078
  Complete submission text file 0001140361-23-006178.txt   528882

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA roiv-20230213.xsd EX-101.SCH 4369
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE roiv-20230213_def.xml EX-101.DEF 18158
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE roiv-20230213_lab.xml EX-101.LAB 28149
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE roiv-20230213_pre.xml EX-101.PRE 20400
8 EXTRACTED XBRL INSTANCE DOCUMENT brhc10048029_8k_htm.xml XML 6557
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE, 2 CHURCH STREET HAMILTON HM11 D0 HM11 441-295-5950
Roivant Sciences Ltd. (Filer) CIK: 0001635088 (see all company filings)

IRS No.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-40782 | Film No.: 23614674
SIC: 2834 Pharmaceutical Preparations